KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 83 filers reported holding KEROS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $603,360 | -17.0% | 18,926 | +4.6% | 0.00% | – |
| Q2 2023 | $727,097 | +78.4% | 18,096 | +89.5% | 0.00% | – |
| Q1 2023 | $407,658 | +5.0% | 9,547 | +18.1% | 0.00% | – |
| Q4 2022 | $388,144 | +35.2% | 8,083 | +5.8% | 0.00% | – |
| Q3 2022 | $287,000 | +51.1% | 7,641 | +10.9% | 0.00% | – |
| Q2 2022 | $190,000 | -49.1% | 6,889 | +0.5% | 0.00% | – |
| Q1 2022 | $373,000 | +3.6% | 6,854 | +11.4% | 0.00% | – |
| Q4 2021 | $360,000 | +48.1% | 6,150 | +0.1% | 0.00% | – |
| Q3 2021 | $243,000 | +57.8% | 6,144 | +69.5% | 0.00% | – |
| Q2 2021 | $154,000 | -27.0% | 3,625 | +6.1% | 0.00% | – |
| Q1 2021 | $211,000 | -13.9% | 3,416 | -1.8% | 0.00% | – |
| Q4 2020 | $245,000 | +665.6% | 3,480 | +315.3% | 0.00% | – |
| Q3 2020 | $32,000 | -23.8% | 838 | -25.7% | 0.00% | – |
| Q2 2020 | $42,000 | – | 1,128 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |